CASI-CASI Pharmaceuticals

# Hot Search #

EVOMELA CNTC19 BI-1206 CID-103

We are CASI

An innovative biopharmaceutical company
focused on hematologic malignancies,
oncology and other unmet medical needs

Learn More

We are CASI

We explore innovative therapies to
save patients' lives

Learn More

About Us

CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. Our goal is to establish a platform for launching medicines in the Greater China market with CASI's experienced China-based regulatory and commercial competencies and proficient global drug development expertise.

Learn More

An innovative biopharmaceutical company focused on unmet medical needs

What We Do

Portfolio

Dedicate to hematologic malignancies & oncology

Products

In August 2019, CASI launched EVOMELA® in China as its first commercial product

Pipeline

We have a strong and growing pipeline of commercially available and clinical-staged drug candidates and continue to acquire assets at commercial and/or clinical development stages through in-license and acquisitions